Share Abbvie among better biotech companies

In the recent years Abbvie had a very positive price momentum. Because of the huge return over the past 5 years of 141 percent the share belongs to the top of the biotech companies. Shares of the sector delivered the past 5 years a gain of at around 106 percent. The average stock of the biotech sector yielded the past 5 year a gain of 106 percent. Other strong winning shares of the sector are Pharming , Galectin Therapeutics Inc and arGEN-X. Rosetta Genomics Ltd, Transgenomic Inc and Versartis Inc. are some of the winning stocks in the sector.

Returns Abbvie versus biotech sector

Buy & hold Returns stock Abbvie over several periods, excluding dividend returns

Since 2012 the stock has a price gain of 141 percent. over the past 90 days the stock made a loss of 11 percent.

Core figures American biotech sector

On average the sector trades costs now 4 times the earnings per share. The sector trades at 2,28 times the book value per share. Since 2012 the sector has a profit of 106 percent and since 2007 a profit of 560 percent.

Over the current book year the total revenue will be 32,91 billion USD (consensus estimates). This is quite more than 2017's revenue of 28,22 billion USD.

Historical revenues and results Abbvie plus estimates 2018

The analysts expect for 2018 a net profit of 12,1 billion USD. For this year the majority of the analysts, consulted by press agency Thomson Reuters, expects a profit per share of 7,78 USD. With this the price/earnings-ratio is 13,24.

Huge dividend Abbvie

Per share the analysts expect a dividend of 3,59 USD per share. The dividend yield is then 3,49 percent. The average dividend yield of the biotech companies is a low 0,5 percent.

Based on the current number of shares Abbvie's market capitalization equals 164,04 billion USD.

Historical stock prices Abbvie

On Wednesday the stock closed at 103,01 USD.

ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.